Artificial intelligence may, in the long term, give humanity the opportunity to cure or prevent most diseases within five to ten years. This is the opinion expressed by Dario Amodei, co‑founder and CEO of Anthropic. The head of the Claude neural network developer published his forecast on August 16 on the social media platform X. He acknowledged that such a forecast may seem overly optimistic even to experts in the field of biology, but he considers it quite realistic, provided that the development of powerful artificial intelligence systems continues at the current pace. An important caveat is that we are not talking about the emergence of some single universal medicine or an already confirmed medical forecast. Rather, this is a scenario that describes how much artificial intelligence can accelerate biological research and the development of new therapeutic methods. Amodai previously outlined this concept in detail in an essay titled Machines of Loving Grace. According to his calculations, a sufficiently powerful artificial intelligence could potentially accelerate the development of biology and medicine by about tenfold, thereby reducing the time it would normally take — from fifty to one hundred years — to five to ten years. Among the possible outcomes of such acceleration, the head of Anthropic cited a sharp decline in cancer incidence and mortality, the prevention or treatment of most genetic diseases, progress in the fight against Alzheimer’s disease, more effective therapy for cardiovascular and autoimmune diseases, as well as new approaches to treating diabetes and obesity. At the same time, Amodai acknowledged that the actual rate of progress would still be constrained by the need to conduct laboratory research, clinical trials, and obtain approvals from regulatory authorities, since artificial intelligence is unable to bypass these stages.

In his new publication, Amodai also reported that Anthropic is rapidly scaling up its work in the fields of biology and medicine. According to him, the company expects to see the first signs of noticeable results in the coming months, with more significant achievements expected in the following years. At the same time, the head of Anthropic emphasized that the artificial intelligence industry as a whole has not yet fulfilled many of its most high‑profile promises. Earlier, the company launched the AI for Science program, which gives researchers access to Anthropic models for projects in the fields of biology, genetics, and the search for new medicines. From the perspective of machine data analysis, Amodei’s statement should be viewed not only as a scientific forecast but also as part of a broader corporate context. According to The Insider, Anthropic’s valuation following the latest funding round exceeded $960 billion, and the company’s expected annual revenue has grown to $47 billion, up from $10 billion for the entire year of 2025. Given such investments, investors have the right to expect not only new versions of Claude but also tangible practical results, and breakthroughs in biology and medicine are one of the few arguments capable of justifying such an assessment in the eyes of the market.